Download PDF
Dtsch Med Wochenschr 2004; 129(5): 204-209
DOI: 10.1055/s-2004-817666
Übersichten
Kardiologie / Labormedizin
© Georg Thieme Verlag Stuttgart · New York

„Neue” Serummarker für das kardiovaskuläre Risiko

Emerging risk factors for cardiovascular diseaseTh Demant1
  • 1Institut für Klinische Chemie und Labormedizin (IKL) (Chefarzt: Prof. Dr. Dr. med. Thomas Demant), Krankenhaus Dresden-Friedrichstadt, Dresden
Further Information

Publication History

eingereicht: 3.6.2003

akzeptiert: 20.11.2003

Publication Date:
21 January 2004 (online)

Also available at
    Permissions and Reprints

Ein erhöhtes LDL-Cholesterin wird heute allgemein als der wichtigste Risikofaktor für kardiovaskuläre Erkrankungen anerkannt. Es ist aber auch klar, dass das individuelle KHK-Risiko eines Patienten durch eine LDL-Cholesterinbestimmung nur sehr unvollständig erfasst wird. Weitere „klassische” Risikofaktoren für die KHK (Hypertonie, erniedrigtes HDL, Diabetes mellitus, Zigarettenrauchen, positive Familienanamnese) erlauben es, das individuelle Risiko für eine zukünftige KHK sehr viel genauer zu ermitteln (siehe z. B. www.chd-taskforce.de). Trotzdem erleidet auch in der Patientengruppe mit der ungünstigsten Risikokonstellation nur ein Teil der Betroffenen einen Herzinfarkt. Neben der Möglichkeit, dass bisher unbekannte kardioprotektive Faktoren existieren, stellt sich die Frage nach weiteren Risikofaktoren, die bisher noch nicht ausreichend berücksichtigt wurden. Lipoprotein(a), Homocystein und C-reaktives Protein sind routinemäßig verfügbare Serumparameter, für die ein Zusammenhang mit kardiovaskulären Erkrankungen belegt ist. Im Folgenden wird dargestellt, welche Bedeutung diese Kenngrößen für die praktische Beurteilung des KHK-Erkrankungsrisikos haben.

Literatur

  • 1 Boemi M, Sirolla C, Fumelli P, James R W. Renal Disease as a Determinant of Increased Lipoprotein(a) Concentrations in Diabetic Patients.  Diabetes Care. 1999;  22 2033-2036
    Google Scholar
  • 2 Bosch T, Lennertz A, Schenzle D, Drager J. Direct adsorption of low-density-lipoprotein and lipoprotein(a) from whole blood: Results of the first clinical long-term multicenter study using DALI apheresis.  J Clin Apheresis. 2002;  17 161-169
    Google Scholar
  • 3 Bostom A G, Shemin D, Lapane K L. et al . High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients.  Kidney Int. 1996;  49 147-152
    Google Scholar
  • 4 Buffon A, Liuzzo G, Biasucci L M. Preprocedural Serum Levels of C-Reactive Protein Predict Early Complications and Late Restenosis After Coronary Angioplasty.  JACC. 1999;  34 1512-1521
    Google Scholar
  • 5 Chambers J C, Obeid O A, Wrigley J, Refsum H, Kooner J S. Improved Vascular Endothelial Function After Oral B Vitamins.  Circulation. 2000;  102 2479-2483
    Google Scholar
  • 6 Chauveau P, Chadefaux B, Coudé M. et al . Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients.  Kidney Int. 1993;  41 72-77
    Google Scholar
  • 7 Chan A W, Bhatt D L, Chew D P. et al . Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions.  Circulation. 2003;  107 1750-1756
    Google Scholar
  • 8 Cremer P, Nagel D, Labrot B. et al . Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).  Eur J Clin Invest. 1994;  24 444-453
    Google Scholar
  • 9 Danesh J, Collins R, Peto R. Lipoprotein(a) and Coronary Heart Disease.  Circulation. 2000;  102 1082-1085
    Google Scholar
  • 10 Danesh J, Whincup P, Walker M. et al . Low Grade Inflammation and Coronary Heart Disease: Prospective Study and Updated Meta-Analyses.  BMJ. 2000;  321 199-204
    Google Scholar
  • 11 de la Pena Diaz A, Cardoso-Saldana G, Zamora-Gonzalez J. et al . Functional approach to investigate Lp(a) in ischemic heart and cerebral diseases.  Eur J Clin Invest. 2003;  33 99-105
    Google Scholar
  • 12 Durand P, Prost M, Loreau N. et al . Impaired Homocysteine Metabolism and Atherothrombotic Disease.  Lab Invest. 2001;  81 645-672
    Google Scholar
  • 13 Eckardstein A, Schulte H, Cullen P, Assmann G. Lipoprotein(a) Further Increases the Risk of Coronary Events in Men With High Global Cardiovascular Risk.  JACC. 2001;  37 434-439
    Google Scholar
  • 14 Freeman D J, Norrie J, Caslake M J. et al . C-Reactive Protein Is an Independent Predictor of Risk for the Development of Diabetes in the West of Scotland Coronary Prevention Study.  Diabetes. 2002;  51 1596-1600
    Google Scholar
  • 15 Hackam D G, Peterson J C, Spence J D. What Level of Plasma Homocyst(e)ine Should Be Treated?.  Am J Hypertens. 2000;  13 105-110
    Google Scholar
  • 16 Haverkate F, Thompson S G, Pyke S DM, Gallimore J R, Pepys M B. Production of C-reaktive protein and risk of coronary events in stable and unstable angina.  Lancet. 1997;  349 462-466
    Google Scholar
  • 17 Heeschen C, Hamm C W, Bruemmer J, Simoons M L. Predictive Value of C-Reactive Protein and Troponin T in Patients With Unstable Angina: A Comparitive Analysis.  JACC. 2000;  35 1535-1542
    Google Scholar
  • 18 Heijer M, Koster T, Blom H J. et al . Hyperhomocysteinemia As a Risk Factor for Deep-Vein-Thrombosis.  NEJM. 1996;  334 759-762
    Google Scholar
  • 19 Homocysteine Lowering Trialists’ Collaboration . Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.  BMJ. 1998;  316 894-898
    Google Scholar
  • 20 Hoogeveen E K, Kostense P J, Jakobs C. et al . Hyperhomocysteinemia Increases Risk of Death, Especially in Typ 2 Diabetes.  Circulation. 2000;  101 1506-1511
    Google Scholar
  • 21 Horne B D, Muhlestein J B, Carlquist J F. et al . Statin Therapy, Lipid Levels, C-Reactive Protein and the Survival of Patients With Angiographically Severe Coronary Artery Disease.  JACC. 2000;  36 1774-1780
    Google Scholar
  • 22 Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in Renal Disease.  Am J Kidney Dis. 1996;  27 1-25
    Google Scholar
  • 23 Lange H W, Dambrink J H, Pasalary M. et al .Folate Therapy Increases In-Stent Restenosis: Results From the Folate After Coronary Intervention Trial (FACIT).- American College of Cardiology, 52nd Annual Scientific Session (www.hartziekten.nl/cardio.nl/ACC2003/ ACCIS-LBCT-II/FACIT.html) 2003
    Google Scholar
  • 24 Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery Disease.  NEJM. 2000;  343 1139-1147
    Google Scholar
  • 25 Malinow M R, Bostom A G, Krauss R M. AHA Science Advisory: Homocysteine, Diet, and Cardiovascular Diseases.  Circulation. 1999;  99 178-182
    Google Scholar
  • 26 Napoli M D, Papa F, Bocola V. C-Reactive Protein in Ischemic Stroke.  Stroke. 2001;  32 917-924
    Google Scholar
  • 27 Nygard O, Nordrehaug J E, Refsum H. et al . Plasma Homocysteine Levels and Mortality in Patients with Coronary Artery Disease.  NEJM. 1997;  337 230-236
    Google Scholar
  • 28 Ockene I S, Matthews C E, Rifai N, Ridker P M, Reed G, Stanek E. Variability and Classification Accuracy of Serial High-Sensitivity C-Reaktive Protein Measurements in Healthy Adults.  Clin Chem. 2001;  47 444-450
    Google Scholar
  • 29 Pearson T A, Mensah G A, Alexander R W. et al . AHA/CDC Scientific Statement: Markers of Inflammation and Cardiovascular Disease.  Circulation. 2003;  107 499-511
    Google Scholar
  • 30 Pradhan A D, Manson J E, Rifai N, Buring J E, Ridker P M. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus.  JAMA. 2001;  286 327-334
    Google Scholar
  • 31 Ridker P M, Buring J E, Cook N R, Rifai N. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events.  Circulation. 2003;  107 391-397
    Google Scholar
  • 32 Ridker P M, Cushman M D, Stampfer M J, Tracy R P, Hennekens C H. Inflammation, Aspirin and the Risk of Cardiovascular Disease in Apparently Healthy Men.  NEJM. 1997;  336 973-979
    Google Scholar
  • 33 Ridker P M, Rifai N, Clearfield M. et al . Measurement of C-Reactive Protein for the Targeting of Statin Therapie in the Primary Prevention of Acute Coronary Events.  NEJM. 2001;  344 1959-1965
    Google Scholar
  • 34 Ridker P M, Rifai N, Pfeffer M A. et al . Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels.  Circulation. 1998;  98 839-844
    Google Scholar
  • 35 Ridker P M, Rifai N, Pfeffer M A, Sacks F. Long-Term Effects of Pravastatin on Plasma Concentration of C-Reactive Protein.  Circulation. 1999;  100 230-235
    Google Scholar
  • 36 Ridker P M, Rifai N, Rose L, Buring J E, Cook N. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.  NEJM. 2002;  347 1557-1565
    Google Scholar
  • 37 Ridker P M, Stampfer M J, Rifai N. Novel Risk Factors for Systemic Atherosclerosis. A Comparison of C-Reactive Protein, Fibrinogen, Homocysteine, Lipoprotein(a), and Standard Cholesterol Screening as Predictors of Peripheral Arterial Disease.  JAMA. 2001;  285 2481-2485
    Google Scholar
  • 38 Rifai N, Ridker P M. Population Distributions of C-reaktive Protein in Apparently Healthy Men and Women in the United States: Implication for Clinical Interpretation.  Clin Chem. 2003;  49 666-669
    Google Scholar
  • 39 Robinson K, Gupta A, Dennis V. et al . Hyperhomocysteinemia Confers an Independent Increased Risk of Atherosclerosis in End-Stage Renal Disease and Is Closely Linked to Plasma Folate and Pyridoxine Concentrations.  Circulation. 1996;  94 2743-2748
    Google Scholar
  • 40 Rossi E, Biasucci L M, Citterio F. et al . Risk of Myocardial Infarction and Angina in Patients With Severe Peripheral Vascular Disease.  Circulation. 2002;  105 800-803
    Google Scholar
  • 41 Rost N S, Wolf P A, Kase C S. et al . Plasma Concentration of C-Reactive Protein and Risk of Ischemic Stroke and Transient Ischemic Attack.  Stroke. 2001;  32 2575-2579
    Google Scholar
  • 42 Schnyder G, Flammer Y, Roffi M, Pin R, Hess O M. Plasma Homocysteine Levels and Late Outcome After Coronary Angioplasty.  JACC. 2002;  40 1769-1776
    Google Scholar
  • 43 Schnyder G, Roffi M, Flammer Y, Pin R, Hess O M. Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamib B6 on Clinical Outcome After Percutaneous Coronary Intervention.  JAMA. 2002;  288 973-979
    Google Scholar
  • 44 Shlipak M G, Simon J A, Vittinghoff E. et al . Estrogen and Progestin, Lipoprotein(a), and the Risk of Recurrent Coronary Heart Disease Events After Menopause.  JAMA. 2000;  283 1845-1852
    Google Scholar
  • 45 Stubbs P J, Al-Obaidi M K, Conroy R M. et al . Effect of Plasma Homocysteine Concentration on Early and Late Events in Patients With Acute Coronary Syndromes.  Circulation. 2000;  102 605-610
    Google Scholar
  • 46 The Homocysteine Studies Collaboration . Homocysteine and Risk of Ischemic Heart Disease and Stroke. A Meta-analysis.  JAMA. 2002;  288 2015-2022
    Google Scholar
  • 47 van Ede A E, Laan R FJM, Blom H J. et al . Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.  Rheumatology. 2002;  41 658-665
    Google Scholar
  • 48 Wald D S, Law M, Morris J K. Homocysteine and cardiovascular disease: evidence on causality from meta-analysis.  Brit Med J. 2002;  325 1202-1209
    Google Scholar
  • 49 Zairis M N, Ambrose J A, Manousakis S J. et al . The Impact of Plasma Levels of C-Reactive Protein, Lipoprotein (a) and Homocysteine on the Long-Term Prognosis After Successful Coronary Stenting.  JACC. 2002;  40 1375-1382
    Google Scholar
  • 50 Zwaka T P, Hombach V, Torzewski J. C-Reactive Protein-Mediated Low Density Lipoprotein Uptake by Macrophages.  Circulation. 2001;  103 1194-1197
    Google Scholar

Prof. Dr. Dr. med. Thomas Demant

Institut für Klinische Chemie und Labormedizin, Krankenhaus Dresden-Friedrichstadt

Friedrichstraße 41

01067 Dresden

Phone: 0351/4803900/3901

Fax: 0351/4803909

Email: demant-th@khdf.de

      >